Abstract:Introduction and Objective The gold standard for the diagnosis of clinicallysignificant portal hypertension isrepresented by HVPG and Upper Gastrointestinalendoscopy is able to indirectlyassess the degree of portalhypertension through the evaluation of esophageal and/or gastric varices. Over the last 20 years, the introduction of non invasive tests (NITs) such asFibroscan has made it possibleto select patients with significantportal hypertension and therefore identify patients eligiblefor endoscopy. The BAVENO VII consensus identifies patientswho could benefit from endoscopy as those patientswith LSM ≥ 20 kPa assessed by TE and platelet count ≤ 150 × 109L. Moreover identifiesvalues of spleen stiffness to rulein and rule out portalhypertension such as SSM >50 kPa and SSM <21 kPa,respectively. Point-shear waveelastography and 2D-shear waveelastography have beenproposed as possible tools to non-invasively assess portalhypertension, but validation of the best cut-off is needed. Aim of this study is the evaluation of the role of 2D-Shear wave in non invasive diagnosis of portalhypertension. Methods From April 2022 to October 2023 we evaluated one hundred patients with chronichepatitis and cirrhosis (50 chronic hepatitis and 50 cirrhosis) whose baseline characteristics are presented in TABLE 1. All patients underwentabdominal ultrasound, liver and spleen stiffness (LS and SS) and liver and spleen 2D-shear wave(L2D-S and S2D-S); FIB-4 and the APRI score were alsocalculated. All cirrhotic patientsunderwent endoscopy to evaluate portal hypertension. Results The prevalence of varices in cirrhotic patients was50%. We found a statisticallysignificant correlation betwen LS and SS (p<0,001) and L2D-S and S2D-S (p<0,001) and the presence of varices, this was true also for APRI and FIB-4 (p<0,001), independently fromage, sex and BMI. We evaluated also the diagnostic performance for each individual test (Table 2), with an optimal cut-off 13.1 kPa and 12.5 kPa for LS and L2D-S (sensitivity 0.83 and 0.79, specificity 0.72 and 0.77, PPV 0.50 and 0.54, NPV 0.93 and 0.92 and AUROC 0.84 and 0.83 respectively), 45 kPa and 25 kPa for SS and S2D-S (sensitivity 0.77 and 0.91, specificity 0.89 and 0.66, PPV 0.69 and 0.47, NPV 0.92 and 0.96 and AUROC 0.88 and 0.80 respectively), 2.82 for FIB-4 (sensitivity 0.84, specificity 0.74, PPV 0.52, NPV 0.93 AUROC 0.80), 0.64 for APRI (sensitivity 0.72, specificity 0.70, PPV 0.44, NPV 0.88 AUROC 0.74). Each single test showed a low PPV for the prediction of oesophagealvarices (OV), however, when we combined the tests together wefound that the combination of LS and S2D-S showed a higher PPV for predicting OV (PPV 0.73; NPV 0.99). Conclusion We foundthat the combination of twotests (Liver stiffness and Spleen stiffness 2D-Shear wave) increases the probability of findingoesophageal varices and therefore can be useful for the non-invasive identification of patients with clinicallysignificant portalhypertension.

Predicting response to non-selective beta-blockers with liver–spleen stiffness and heart rate in patients with liver cirrhosis and high-risk varices

Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients

Prognostic Value of Virtual Portal Pressure Gradient Response in Compensated Cirrhotic Patients Treated with Carvedilol.

Increase in Free Hepatic Venous Pressure Response to Beta-Blockers Predicts Variceal Bleeding in Cirrhotic Patients

Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response

Role of P-shear wave hepatic elastography in prediction of high-risk varices in patients affected by compensated advanced chronic liver disease

Heterogeneity of treatment response to beta-blockers in the treatment of portal hypertension: A systematic review

Nomogram for predicting the risk of gastroesophageal varices after primary endoscopic prophylaxis for variceal hemorrhage in patients with cirrhosis

Non-selective beta-blockers lower the risk of first decompensation in patients with cirrhosis and enduring clinically significant portal hypertension after etiological treatment

Spleen stiffness: a new tool to predict high‐risk varices in cirrhotic patients

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trials

Non-invasive model for predicting high-risk esophageal varices based on liver and spleen stiffness

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience

Baveno-VII Criteria to Predict Decompensation and Initiate Non-Selective Beta-Blocker in Compensated Advanced Chronic Liver Disease Patients

Non-Invasive Prediction Models for Esophageal Varices and Red Signs in Patients With Hepatitis B Virus-Related Liver Cirrhosis

Liver stiffness-spleen diameter to platelet ratio score (LSPS model) predicts variceal rebleeding for cirrhotic patients

Performance evaluation of hepatic venous pressure gradient (HVPG) score as predictor tool of liver-related events in patients with advanced chronic liver disease

New Model Predicting Gastroesophageal Varices and Variceal Hemorrhage in Patients with Chronic Liver Disease

A New Algorithm for Predicting Long-Term Survival in Chronic Hepatitis B Patients with Variceal Bleeding after Endoscopic Therapy.

Development and validation of a machine learning-based model for varices screening in compensated cirrhosis (CHESS2001): An international multicenter study

The role of 2D-Shearwave elastography in non invasive portal hypertension diagnosis